Evidence map›Paper›PMID 25036040›Full record

ArticlePloS one2014

Integrating genomics and proteomics data to predict drug effects using binary linear programming.

Zhiwei Ji, Jing Su, Chenglin Liu, Hongyan Wang, Deshuang Huang, Xiaobo Zhou

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Zhiwei JiDivision of Radiologic Sciences - Center for Bioinformatics and Systems Biology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina, United States of America; School of Electronics and Information Engineering, Tongji University, Shanghai, P.R. China.
Jing SuDivision of Radiologic Sciences - Center for Bioinformatics and Systems Biology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina, United States of America.
Chenglin LiuDivision of Radiologic Sciences - Center for Bioinformatics and Systems Biology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina, United States of America.
Hongyan WangDivision of Radiologic Sciences - Center for Bioinformatics and Systems Biology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina, United States of America.
Deshuang HuangSchool of Electronics and Information Engineering, Tongji University, Shanghai, P.R. China.
Xiaobo ZhouDivision of Radiologic Sciences - Center for Bioinformatics and Systems Biology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina, United States of America.
Wake Forest University · USTongji University · CN

Funding

Modelling the Growth of the MIC Niche at the System LevelU01CA166886 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ZHOU, XIAOBO · 2012 to 2016
$2.2M
itNETZ: Integrative and Translational Network-based Cellular Signature AnalyzerU01HL111560 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ZHOU, XIAOBO · 2011 to 2013
$1.1M
NCI NIH HHS U01 CA166886NCI NIH HHS U01CA166886-03NHLBI NIH HHS U01 HL111560NHLBI NIH HHS U01HL111560-04
6 · The paper itself

Abstract

The Library of Integrated Network-Based Cellular Signatures (LINCS) project aims to create a network-based understanding of biology by cataloging changes in gene expression and signal transduction that occur when cells are exposed to a variety of perturbations. It is helpful for understanding cell pathways and facilitating drug discovery. Here, we developed a novel approach to infer cell-specific pathways and identify a compound's effects using gene expression and phosphoproteomics data under treatments with different compounds. Gene expression data were employed to infer potential targets of compounds and create a generic pathway map. Binary linear programming (BLP) was then developed to optimize the generic pathway topology based on the mid-stage signaling response of phosphorylation. To demonstrate effectiveness of this approach, we built a generic pathway map for the MCF7 breast cancer cell line and inferred the cell-specific pathways by BLP. The first group of 11 compounds was utilized to optimize the generic pathways, and then 4 compounds were used to identify effects based on the inferred cell-specific pathways. Cross-validation indicated that the cell-specific pathways reliably predicted a compound's effects. Finally, we applied BLP to re-optimize the cell-specific pathways to predict the effects of 4 compounds (trichostatin A, MS-275, staurosporine, and digoxigenin) according to compound-induced topological alterations. Trichostatin A and MS-275 (both HDAC inhibitors) inhibited the downstream pathway of HDAC1 and caused cell growth arrest via activation of p53 and p21; the effects of digoxigenin were totally opposite. Staurosporine blocked the cell cycle via p53 and p21, but also promoted cell growth via activated HDAC1 and its downstream pathway. Our approach was also applied to the PC3 prostate cancer cell line, and the cross-validation analysis showed very good accuracy in predicting effects of 4 compounds. In summary, our computational model can be used to elucidate potential mechanisms of a compound's efficacy.

Indexed as

Antineoplastic AgentsBenzamidesBreast NeoplasmsCell CycleCell Line, TumorCyclin-Dependent Kinase Inhibitor p21DigoxigeninFemaleGene ExpressionGene Regulatory NetworksGenomicsHistone Deacetylase InhibitorsHL-60 CellsHumansHydroxamic AcidsMCF-7 CellsAntineoplastic AgentsBenzamidesCyclin-Dependent Kinase Inhibitor p21DigoxigeninentinostatHistone Deacetylase InhibitorsHydroxamic AcidsProteomePyridinesStaurosporinetrichostatin ATumor Suppressor Protein p53

Identifiers

PMID25036040
PMCPMC4103865
OpenAlexW2054006575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.